Current approaches in tamper-resistant and abuse-deterrent formulations

Drug Development and Industrial Pharmacy

Volumn 39, Issue 5, 2013, Pages 611-624

  Mastropietro, David J ^a   Omidian, Hossein ^a  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

Author keywords

Chemical approaches; Diversion; Drug abuse; Drug formulation; Physical approaches; Prescription opioids

Indexed keywords

ACURACET; ALPRAZOLAM; AMPHETAMINE; BUPRENORPHINE; CENTRAL DEPRESSANT AGENT; CENTRAL STIMULANT AGENT; CODEINE; COL 172; DETERX; DEXAMPHETAMINE; DIAZEPAM; EG P 066; EG P 113; EG P 114; EG P 118; FENTANYL; HYDROCODONE; HYDROMORPHONE; INTELLITAB; LISDEXAMFETAMINE; METHYLPHENIDATE; MORPHINE; NICOTINIC ACID; NICOTINIC ACID PLUS OXYCODONE; OPIATE; OXYCODONE; OXYMORPHONE; PRODRUG; SECUREL; UNCLASSIFIED DRUG; VYCAVERT;

AERATION; CHEMICAL MODIFICATION; DRUG ABUSE; DRUG APPROVAL; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG INDUSTRY; DRUG ISOLATION; DRUG MISUSE; DRUG TRANSFORMATION; EUPHORIA; GEL; HEALTH HAZARD; HUMAN; INGESTION; INHALATION; INJECTION; MASTICATION; MAXIMUM PLASMA CONCENTRATION; PACKAGING; PARTICLE SIZE; PRESCRIPTION; REVIEW; TABLET; TRANSDERMAL PATCH; VOLATILIZATION;

CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; DRUG INDUSTRY; DRUG PRESCRIPTIONS; HUMANS; PHARMACEUTICAL PREPARATIONS; PRESCRIPTION DRUG MISUSE; PRODRUGS;

EID: 84875884667     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.680468     Document Type: Review

References (93)

1. Substance abuse and mental health services administration. Results from the 2009 national survey on drug use and health: volume I. summary of national findings. Office of applied studies, NSDUH series H-38A. HHS publication no SMA 10-4586 Findings, Rockville, MD, 2010.
2. Friedman RA. (2006). The changing face of teenage drug abuse - The trend toward prescription drugs. N Engl J Med, 354:1448-1450.
3. Substance abuse and mental health services administration. Treatment episode data set (TEDS): 1998-2008. State admissions to substance abuse treatment services. Center for behavioral health statistics and quality, DASIS series: S-55. HHS publication no (SMA) 10-4613, Rockville, MD, 2010.
4. American pain society. (1996). Advocacy: The use of opioids for the treatment of chronic pain, a consensus statement from American academy of pain medicine and American pain society [Online]. Available at: http://www.ampainsoc. org/advocacy/opioids.htm. Accessed on 22 March 2011.
5. Friedman RA. (2006). The changing face of teenage drug abuse-the trend toward prescription drugs. N Engl J Med, 354:1448-1450.
6. Manchikanti L. (2007). National drug control policy and prescription drug abuse: Facts and fallacies. Pain Physician, 10:399-424.
7. Substance abuse and mental health services administration. Results from the 2008 national survey on drug use and health: National findings. Office of applied studies, NSDUH series H-36. HHS publication no SMA 09-4434 Rockville, MD, 2009.
8. Ford JA, Lacerenza C. (2011). The relationship between source of diversion and prescription drug misuse, abuse, and dependence. Subst Use Misuse, 46:819-827.
9. The national center on addiction and substance abuse (CASA) at Columbia University. Under the counter: The diversion and abuse of controlled prescription drugs in the US New York, NY, 2005. Available at: http://www.casacolumbia.org/articlefiles/380-Under%20the%20Counter%20- %20Diversion.pdf. Accessed on 15 February 2011.
10. Johnston LD, O'Malley PM, Bachman JG, et al. (2011). Monitoring the future, national results on adolescent drug use: Overview of key findings, 2010 [Online]. Institute for social research, University of Michigan, Ann Arbor. Available at: http://www. monitoringthefuture.org/pubs/monographs/mtf- overview2010. pdf. Accessed on 18 March 2011.
11. Levine SB, Coupey SM. (2009). Nonmedical use of prescription medications: An emerging risk behavior among rural adolescents. J Adolesc Health, 44:407-409.
12. Substance abuse and mental health services administration. Center for behavioral health statistics and quality. The DAWN report: Drugrelated emergency department visits involving pharmaceutical misuse and abuse by older adults. Rockville, MD, 2010. Available at: http://www.samhsa.gov/data/2k10/ WebSR018Pharma50+/Pharma50+HTML.pdf. Accessed on 19 March 2011.
13. Center for lawful access and abuse deterrence. (2009). The national prescription drug abuse prevention strategy 2009 [Online]. Available at: http://claad.org/downloads/Nat-Prescipt-Drug-Abuse-Prev-Strat-2009.pdf. Accessed on 17 March 2011.
14. Schneider JP, Matthews M, Jamison RN. (2010). Abuse-deterrent and tamper-resistant opioid formulations: What is their role in addressing prescription opioid abuse? CNS Drugs, 24:805-810.
15. Katz NP, Adams EH, Chilcoat H, Colucci RD, Comer SD, Goliber P et al. (2007). Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain, 23:648-660.
16. National association of drug diversion investigators inc. (2011). Abused pharmaceutical substances [Online]. Available at: http://naddi. associationdatabase.com/aws/NADDI/pt/sp/abused-rx. Accessed on 22 March 2011.
17. National institute on drug abuse. (2009). NIDA InfoFacts: Prescription and over-the-counter medications [Online]. Available at: http://www.drugabuse. gov/PDF/Infofacts/PainMed09.pdf. Accessed on 25 February 2011.
18. Foye WO, Lemke TL, Williams DA. Foye's principles of medicinal chemistry. 6th ed. Series. Philadelphia: Lippincott Williams & Wilkins, 2008:652-653.
19. Skerritt JH, Johnston GA. (1983). Enhancement of GABA binding by benzodiazepines and related anxiolytics. Eur J Pharmacol, 89:193-198.
20. Sulzer D, Sonders MS, Poulsen NW, Galli A. (2005). Mechanisms of neurotransmitter release by amphetamines: A review. Prog Neurobiol, 75:406-433.
21. The national institute on drug abuse. (2007). Methamphetamine addiction: Cause for concern-hope for the future [Online]. Available at: http://www.drugabuse.gov/tib/meth.html. Accessed on 22 March 2011.
22. Passik SD, Hays L, Eisner N, Kirsh KL. (2006). Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother, 20:5-13.
23. McCabe SE, Cranford JA, Morales M, Young A. (2006). Simultaneous and concurrent polydrug use of alcohol and prescription drugs: Prevalence, correlates, and consequences. J Stud Alcohol, 67:529-537.
24. US Food and Drug Administration. (2005). Information for healthcare professionals: hydromorphone hydrochloride extended-release capsules (marketed as Palladone), [Online]. Available at: http://www.fda.gov/Drugs/DrugSafety/ Postmarket DrugSafetyInformationforPatientsandProviders/ucm129288. htm. Accessed on 4 April 2011.
25. Jayawant SS, Balkrishnan R. (2005). The controversy surrounding OxyContin abuse: Issues and solutions. Ther Clin Risk Manag, 1:77-82.
26. Meng Y, Lichtman AH, Bridgen DT, Martin BR. (1997). Inhalation studies with drugs of abuse. NIDA Res Monogr, 173:201-224.
27. Prosser JM, Jones BE, Nelson L. (2010). Complications of oral exposure to fentanyl transdermal delivery system patches. J Med Toxicol, 6:443-447.
28. Marquardt KA, Tharratt RS, Musallam NA. (1995). Fentanyl remaining in a transdermal system following three days of continuous use. Ann Pharmacother, 29:969-971.
29. Cone EJ. (2006). Ephemeral profiles of prescription drug and formulation tampering: Evolving pseudoscience on the Internet. Drug Alcohol Depend, 83 Suppl 1:S31-S39.
30. Goldberg AP. Transdermal delivery form disposal systems and methods. US patent application no.12/048771 (2008).
31. Marcenyac G, Alfonso M, Gehrlein L, et al. Disposal system for transdermal dosage form. US patent application no.10/476032 (2002).
32. US7867511
33. Anderson CR, Morris RL, Anderson C, et al. Abuse potential reduction in abusable substance dosage form. US7867511 (2011) 33. Tavares L, Reidenberg BE, Sackler RS, et al. Abuse resistant opioid containing transdermal systems. US patent application no.10/476601 (2002).
34. US Food and Drug Administration. (2009). Risk evaluation and mitigation strategies (REMS) and opioid analgesics webinar [Online]. Available at: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm163655.htm. Accessed on 23 March 2011.
35. Woodcock J. A difficult balance-pain management, drug safety, and the FDA. N Engl J Med 2009; 361:2105-7.
36. US Food and Drug Administration. (2009). Background on opioid REMS [Online]. Available at: http://www.fda.gov/drugs/drugsafety/ informationbydrugclass/ucm187975. Accessed on 23 March 2011.
37. Center for drug evaluation and research. (2010). (Draft) Guidance for industry, assessment of abuse potential of drugs [Online]. US Food and Drug Administration. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM198650.pdf. Accessed on 16 January 2011.
38. Tolliver JM. (2010). Premarketing assessment of abuse deterrent formulations [Online]. Center for Drug Evaluation and Research, US Food and Drug Administration. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/ UCM 233240.pdf. Accessed on 23 March 2011.
39. Hamed E, Moe D. Development of tamper deterrent formulations: State of the pharmaceutical industry. Curr Drug Abuse Rev 2010; 3:139-146.
40. Webster L. Update on abuse-resistant and abuse-deterrent approaches to opioid formulations. Pain Med 2009; 10 Suppl 2:S124-33.
41. Coleman JJ, Schuster CR, DuPont RL. Reducing the abuse potential of controlled substances. Pharmaceutical Medicine 2010; 24:21-36.
42. Hirsh JC, Fleming AB, Rariy RV, et al. Abuse-deterrent drug formulations. US7771707 (2010).
43. Cicero TJ, Inciardi JA, Muñoz A. (2005). Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. J Pain, 6:662-672.
44. US Food and Drug Administration. (2010). FDA approves new formulation for OxyContin® [Online]. Available at: http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm207480.htm. Accessed on 17 January 2011.
45. Purdue Pharma L.P. (2011). Purdue's prescription drug products [Online]. Available at: http://www.purduepharma.com/Products/Prescription/Pages/default. aspx. Accessed on 23 March 2011.
46. Purdue Pharma L.P. (2008). Purdue meeting background materials, NDA 22-272 reformulated OxyContin®, joint meeting of the anesthetic and life support drugs advisory committee and drug safety and risk management advisory committee [Online]. Available at: http://www.fda.gov/ohrms/dockets/ac/08/ briefing/2008-4356b1-02-Purdue.pdf. Accessed on 14 April 2011.
47. DURECT Corporation. ORADUR® gel cap system [Online]. Available at: http://www.durect.com/wt/durect/page-name/oradur. Accessed on 14 January 2011.
48. Lu Y, Yu Y, Tang X. (2007). Sucrose acetate isobutyrate as an in situ forming system for sustained risperidone release. J Pharm Sci, 96:3252-3262.
49. Pain Therapeutics Inc. (2008). NDA 22-324 Remoxy XRT, advisory committee briefing materials for the anesthetic life support drugs advisory committee meeting of November 13, 2008 [Online]. Available at: http://www.fda.gov/ohrms/ dockets/ac/08/briefing/2008-4395b1-02-PAIN.pdf. Accessed on 17 March 2011.
50. Zamloot M, Chao W, Kang LL, et al. Remoxy®: A novel formulation of extended release oxycodone developed using the ORADUR®technology. J Appl Res 2010;10:88-96.
51. Friedmann N, Butera P, Klutzaritz V, et al. (2008). Remoxy, an abuse-resistant controlled-release oxycodone, treats chronic pain [Online]. Available at: http://www.paintrials.com/publications/Remoxy-PTI-821-CO.pdf. Accessed on 27 March 2011.
52. Gilderman L, Butera PG, Gilmore D, et al. (2006). Remoxy™: A new opioid drug with effective analgesia and abuse-resistance [Online]. Available at: http://www.paintrials.com/aps/Remoxy-APSposter.pdf. Accessed on 27 March 2011.
53. Pain Therapeutics Inc. (2011). FDA complete response letter received for REMOXY [Online]. Available at: http://investor. paintrials.com/releasedetail. cfm?ReleaseID=587311. Accessed on 20 March 2011.
54. DuPont RL, Lande SD. The impact of abuse deterrent formulation on the incidence of abuse and diversion of OROSOR methylphenidate. Drug Alcohol Depend 2006; 83:S87.
55. Parasrampuria DA, Schoedel KA, Schuller R, Silber SA, Ciccone PE, Gu J et al. (2007). Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users. J Clin Psychopharmacol, 27:459-467.
56. Shannon HE, Su TP. (1982). Effects of the combination of tripelennamine and pentazocine at the behavioral and molecular levels. Pharmacol Biochem Behav, 17:789-795.
57. Reed DA, Schnoll SH. (1986). Abuse of pentazocine-naloxone combination. JAMA, 256:2562-2564.
58. Lahmeyer HW, Craig RJ. (1987). Pentazocine-naloxone: Another 'addiction-proof' drug of abuse. Int J Addict, 22:1163-1166.
59. Reckitt Benckiser Pharmaceuticals Inc. (2011). SUBOXONE film, key benefits [Online]. Available at: http://www.suboxone.com/hcp/about-suboxone/key- benefits.aspx. Accessed on 25 March 2011.
60. Greene P. (2010). Outpatient drug utilization trends for buprenorphine years 2002-2009, US Food and Drug Administration, division of epidemiology [Online]. Available at: http://buprenorphine.samhsa.gov/bwns/2010-presentations- pdf/09-Greene-508.pdf. Accessed on 5 March 2011.
61. Stinchcomb AL, Golinski MJ, Hammell DC, et al. Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs. US7511054 (2009).
62. Oshlack B, Wright C, Haddox JD. Tamper-resistant oral opioid agonist formulations. US7842311 (2010).
63. Sackler R. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant. US7332182 (2008).
64. Oshlack B, Wright C, Breder C. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent. US7842307 (2010).
65. King Pharmaceuticals Inc. (2009). EMBEDA® prescribing information [Online]. Available at: http://www.kingpharm.com/products/product-document.cfm? brand-name=Embeda&product-specific-name=CII&document-type-code=PI. Accessed on 20 April 2011.
66. King Pharmaceuticals Inc. (2011). EMBEDA® important information for patients and prescribers [Online]. Available at: http://www.embeda.com/. Accessed on 24 March 2011.
67. Alpharma Pharmaceuticals LLC. (2010). EMBEDA® extended release capsules: joint anesthetic and life support drugs (ALSDAC) and drug safety and risk management (DSaRM) advisory committee briefing document [Online]. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM230111.pdf. Accessed on 3 March 2011.
68. Passik SD. (2009). Issues in long-term opioid therapy: Unmet needs, risks, and solutions. Mayo Clin Proc, 84:593-601.
69. Dew RE, Kollins SH. (2010). Lisdexamfetamine dimesylate: A new option in stimulant treatment for ADHD. Expert Opin Pharmacother, 11:2907-2913.
70. Jasinski DR, Krishnan S. (2009). Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse. J Psychopharmacol (Oxford), 23:419-427.
71. Mickle T, Krishnan S, Moncrief JS, et al. Abuse-resistant hydrocodone compounds. US7375082 (2008).
72. Ruan X, Chen T, Gudin J, Couch JP, Chiravuri S. (2010). Acute opioid withdrawal precipitated by ingestion of crushed embeda (morphine extended release with sequestered naltrexone): Case report and the focused review of the literature. J Opioid Manag, 6:300-303.
73. Bear D. Material for controlling diversion of medications. US7226619 (2007).
74. Pfizer Inc. (2005). Lomotil® US Physician Prescribing Information [Online]. Available at: http://www.pfizer.com/files/products/uspi-lomotil.pdf. Accessed on 23 March 2011.
75. Acura Pharmaceuticals Inc. (2011). Acurox® with niacin tablets [Online]. Available at: http://acurapharm.com/products/acuroxtablets/.Accessed on 18 March 2011.
76. Acura Pharmaceuticals Inc. (2011). Study AP-ADF-107, a phase II single-center, randomized, double-blind study in fasted and non-fasted healthy volunteers to evaluate the dose response for flushing and safety and tolerability of escalating doses of niacin [Online]. Available at: http://acurapharm.com/products/acurox-tablets/study-ap-adf-107/. Accessed on 18 March 2011.
77. Davidson MH. Niacin use and cutaneous flushing: Mechanisms and strategies for prevention. Am J Cardiol 2008; 101:14B-19B.
78. Xanodyne Pharmaceuticals Inc. (2008). Roxicodone® prescribing information [Online]. Available at: http://www.accessdata.fda. gov/drugsatfda-docs/label/2009/021011s002lbl.pdf. Accessed on 25 March 2011.
79. Kumar V, Dixon D, Tewari D, et al. Methods and compositions for deterring abuse of opioid containing dosage forms. US7476402 (2009).
80. Kumar V, Dixon D, Tewari D, et al. Methods and compositions for deterring abuse of opioid containing dosage forms. US7510726 (2009).
81. Kumar V, Dixon D, Tewari D, et al. Methods and compositions for deterring abuse of opioid containing dosage forms. US7201920 (2007).
82. Oshlack B, Colucci R, Wright C, et al. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent. US7144587 (2006).
83. Frank ME, Bouverat BP, MacKinnon BI, Hettinger TP. (2004). The distinctiveness of ionic and nonionic bitter stimuli. Physiol Behav, 80:421-431.
84. Brushwood DB, Rich BA, Coleman JJ, Bolen J, Wong W. (2010). Legal liability perspectives on abuse-deterrent opioids in the treatment of chronic pain. J Pain Palliat Care Pharmacother, 24:333-348.
85. Katz N. (2008). Abuse-deterrent opioid formulations: Are they a pipe dream? Curr Rheumatol Rep, 10:11-18.
86. Fishman SM, Papazian JS, Gonzalez S, Riches PS, Gilson A. (2004). Regulating opioid prescribing through prescription monitoring programs: Balancing drug diversion and treatment of pain. Pain Med, 5:309-324.
87. Acura Pharmaceuticals Inc. (2011). Impede™ technology [Online]. Available at: http://acurapharm.com/researchdevelopment/impede-technology/. Accessed on 25 March 2011.
88. European medicines agency.Committee for medicinal products for human use (CHMP). Guideline on clinical development of fixed combination medicinal products. 2009;CHMP/EWP/240/95.
89. European medicines agency. (2006). Suboxone: EPARScientific Discussion [Online]. Available at: http://www.ema. europa.eu/docs/en-GB/document-library/ EPAR-Scientific-Discussion/human/000697/WC500058497.pdf. Accessed on 28 Dec 2011.
90. Johnson F, Ciric S, Boudriau S, Swearingen D, Stauffer J. (2010). Food effects on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules. Adv Ther, 27:846-858.
91. Stauffer J, Setnik B, Sokolowska M, Romach M, Johnson F, Sellers E. (2009). Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: A randomized, double-blind, placebo-controlled, crossover study. Clin Drug Investig, 29:777-790.
92. Raffa RB, Pergolizzi JV Jr. (2010). Opioid formulations designed to resist/deter abuse. Drugs, 70:1657-1675.
93. Lennernäs H. (2009). Ethanol-drug absorption interaction: Potential for a significant effect on the plasma pharmacokinetics of ethanol vulnerable formulations. Mol Pharm, 6: 1429-1440.